You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Research & Development
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Galmed Pharmaceuticals to acquire Colospan for GI-focused platform development

Alvotech reports FDA review acceptance for Entyvio biosimilar candidate AVT16

Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector

Bayer reports positive Phase III FIND-CKD results for Kerendia in non-diabetic chronic kidney disease

Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline

Lupin's Ranluspec (ranibizumab) injection receives US FDA approval

Pharming secures FDA acceptance of Joenja filing for children with APDS

ADC Therapeutics reports trial results for ZYNLONTA - rituximab combination in relapsed or refractory diffuse large B-Cell lymphoma

Medtronic seeks expanded US approvals for Hugo robotic surgery system

MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors

Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection

Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan

FDA accepts Genentech's giredestrant application for early-stage breast cancer

Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC

Haisco receives US FDA approval for anaesthetic Cipepofol

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026